Stock Events

Stock Events

EOM Pharmaceutical 

$0.17
9
+$0.01+6.92% Wednesday 20:00

Statistics

Day High
0.16
Day Low
0.16
52W High
0.34
52W Low
0.04
Volume
100
Avg. Volume
3,345
Mkt Cap
21.51M
P/E Ratio
0.02
Dividend Yield
-
Dividend
-

Earnings

23NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-0.03
-0.02
-0.01
0
Expected EPS
0
Actual EPS
0

Financials

-Profit Margin
Unprofitable
2018
2020
2021
2022
2023
2024
0Revenue
-3.78MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMUC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is a leading biopharmaceutical company focusing on cancer, a key area for EOM Pharmaceutical, making them direct competitors in oncology treatments.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. specializes in pharmaceuticals, including cancer treatments that directly compete with EOM Pharmaceutical's oncology-focused pipeline.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global biopharmaceutical company with a broad range of products, including oncology, which competes with EOM Pharmaceutical's cancer treatment research.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. focuses on antiviral drugs for infections like HIV, liver diseases, and oncology, competing with EOM Pharmaceutical in the development of treatments for cancer.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotechnology company focusing on human therapeutics, including oncology, which competes with EOM Pharmaceutical's focus on cancer treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis AG is a global healthcare company that operates in various segments, including innovative medicines with a strong focus on oncology, competing with EOM Pharmaceutical.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. is a research-based biopharmaceutical company with a significant focus on oncology, directly competing with EOM Pharmaceutical in cancer treatment research.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a pioneer in healthcare, focusing on pharmaceuticals and diagnostics in oncology, making it a competitor to EOM Pharmaceutical in cancer treatment advancements.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including in oncology, competing with EOM Pharmaceutical.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a diverse healthcare company with a strong pharmaceutical division focusing on oncology among other areas, competing with EOM Pharmaceutical in developing cancer treatments.

About

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company, which engages in the development of drugs with the potential to transform therapeutic paradigms. Its pipeline includes EOM613 and EOM147. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.
Show more...
CEO
Dr. Irach B. Taraporewala B.S., M.S., Ph.D.
Employees
3
Country
US
ISIN
US4525364026

Listings

OTC Link
US
IMUC

0 Comments

Share your thoughts

FAQ

What is EOM Pharmaceutical stock price today?▼
The current price of IMUC is $0.17 USD — it has increased by +6.92% in the past 24 hours. Watch EOM Pharmaceutical stock price performance more closely on the chart.
What is EOM Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange EOM Pharmaceutical stocks are traded under the ticker IMUC.
Is EOM Pharmaceutical stock price growing?▼
IMUC stock has risen by +6.92% compared to the previous week, the month change is a +53.15% rise, over the last year EOM Pharmaceutical has showed a +10.39% increase.
What is EOM Pharmaceutical market cap?▼
Today EOM Pharmaceutical has the market capitalization of 21.51M
What were EOM Pharmaceutical earnings last quarter?▼
IMUC earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is EOM Pharmaceutical revenue for the last year?▼
EOM Pharmaceutical revenue for the last year amounts to 0 USD.
What is EOM Pharmaceutical net income for the last year?▼
IMUC net income for the last year is -3.78M USD.
How many employees does EOM Pharmaceutical have?▼
As of April 03, 2026, the company has 3 employees.
In which sector is EOM Pharmaceutical located?▼
EOM Pharmaceutical operates in the Health Care sector.
When did EOM Pharmaceutical complete a stock split?▼
The last stock split for EOM Pharmaceutical was on September 16, 2020 with a ratio of 1:10.
Where is EOM Pharmaceutical headquartered?▼
EOM Pharmaceutical is headquartered in Montvale, US.